{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T04:41:36Z","timestamp":1766378496515,"version":"3.37.3"},"reference-count":36,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To determine whether ACE inhibitors reduce the risk of type 2 diabetes using a Mendelian randomization (MR) approach.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>A two-sample MR analysis included 17 independent genetic variants associated with ACE serum concentration in 4,147 participants from the Outcome Reduction with Initial Glargine INtervention (ORIGIN) (clinical trial reg. no. NCT00069784) trial, and their effects on type 2 diabetes risk were estimated from 18 studies of the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium. A genetic risk score (GRS) underpinning lower ACE concentration was then tested for association with type 2 diabetes prevalence in 341,872 participants, including 16,320 with type 2 diabetes, from the UK Biobank. MR estimates were compared after standardization for blood pressure change, with the estimate obtained from a randomized controlled trial (RCT) meta-analysis of ACE inhibitors versus placebo (n = 31,200).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Genetically lower ACE concentrations were associated with a lower risk of type 2 diabetes (odds ratio [OR] per SD 0.92 [95% CI 0.89\u20130.95]; P = 1.79 \u00d7 10\u22127). This result was replicated in the UK Biobank (OR per SD 0.97 [0.96\u20130.99]; P = 8.73 \u00d7 10\u22124). After standardization, the ACE GRS was associated with a larger decrease in type 2 diabetes risk per 2.4-mmHg lower mean arterial pressure (MAP) compared with that obtained from an RCT meta-analysis (OR per 2.4-mmHg lower MAP 0.19 [0.07\u20130.51] vs. 0.76 [0.60\u20130.97], respectively; P = 0.007 for difference).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>These results support the causal protective effect of ACE inhibitors on type 2 diabetes risk and may guide therapeutic decision making in clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc19-1973","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T03:39:20Z","timestamp":1580873960000},"page":"835-842","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":33,"title":["ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study"],"prefix":"10.2337","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct00069784","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marie","family":"Pigeyre","sequence":"first","affiliation":[{"name":"Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada"},{"name":"Thrombosis and Atherosclerosis Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada"},{"name":"Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Sjaarda","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada"},{"name":"Thrombosis and Atherosclerosis Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada"},{"name":"Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Chong","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada"},{"name":"Thrombosis and Atherosclerosis Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada"},{"name":"Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Hess","sequence":"additional","affiliation":[{"name":"R&D, Translational Medicine & Early Development, Biomarkers & Clinical Bioanalyses, Sanofi Aventis Deutschland GmbH, Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie","family":"Bosch","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada"},{"name":"School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada"},{"name":"Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-2836","authenticated-orcid":false,"given":"Hertzel","family":"Gerstein","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada"},{"name":"Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-4760","authenticated-orcid":false,"given":"Guillaume","family":"Par\u00e9","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada"},{"name":"Thrombosis and Atherosclerosis Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada"},{"name":"Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"2022031223501123300_B1","unstructured":"World Health Organization\n          . The top 10 causes of death [Internet]. Available from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. Accessed 9 May 2019"},{"key":"2022031223501123300_B2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(14)70102-0","article-title":"Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment","volume":"2","author":"Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031223501123300_B3","unstructured":"World Health Organization\n          . Diabetes [Internet]. Available from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes. Accessed 9 May 2019"},{"key":"2022031223501123300_B4","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.2337\/dc18-S005","article-title":"5. Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031223501123300_B5","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","article-title":"Ramipril and the development of diabetes","volume":"286","author":"Yusuf","year":"2001","journal-title":"JAMA"},{"key":"2022031223501123300_B6","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"2022031223501123300_B7","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000054611.89228.92","article-title":"Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"2022031223501123300_B8","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"2022031223501123300_B9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/eurheartj\/ehn026","article-title":"Impact of previous percutaneous transluminal coronary angioplasty and\/or stenting revascularization on outcomes after surgical revascularization: insights from the imagine study","volume":"29","author":"Chocron","year":"2008","journal-title":"Eur Heart J"},{"key":"2022031223501123300_B10","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes","volume":"355","author":"Bosch","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031223501123300_B11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrcardio.2017.78","article-title":"Mendelian randomization in cardiometabolic disease: challenges in evaluating causality","volume":"14","author":"Holmes","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2022031223501123300_B12","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/ije\/dyx207","article-title":"Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities","volume":"46","author":"Walker","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2022031223501123300_B13","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.2337\/db16-1253","article-title":"An expanded genome-wide association study of type 2 diabetes in Europeans","volume":"66","author":"Scott","year":"2017","journal-title":"Diabetes"},{"key":"2022031223501123300_B14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031223501123300_B15","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"2022031223501123300_B16","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1210\/jc.2017-00273","article-title":"Validation of the ORIGIN cardiovascular biomarker panel and the value of adding troponin I in dysglycemic people","volume":"102","author":"Gerstein","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031223501123300_B17","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2337\/dc18-2444","article-title":"Identification of novel causal blood biomarkers linking metabolically favorable adiposity with type 2 diabetes risk","volume":"42","author":"Pigeyre","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031223501123300_B18","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"2022031223501123300_B19","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.1038\/s41598-017-13056-1","article-title":"A machine-learning heuristic to improve gene score prediction of polygenic traits","volume":"7","author":"Par\u00e9","year":"2017","journal-title":"Sci Rep"},{"key":"2022031223501123300_B20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature14177","article-title":"Genetic studies of body mass index yield new insights for obesity biology","volume":"518","author":"Locke","year":"2015","journal-title":"Nature"},{"key":"2022031223501123300_B21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2022031223501123300_B22","doi-asserted-by":"crossref","first-page":"E435","DOI":"10.1152\/ajpendo.00391.2014","article-title":"Modulation of glucose metabolism by the renin-angiotensin-aldosterone system","volume":"308","author":"Favre","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031223501123300_B23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/ng.520","article-title":"New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk","volume":"42","author":"Dupuis","year":"2010","journal-title":"Nat Genet"},{"key":"2022031223501123300_B24","doi-asserted-by":"crossref","first-page":"e1004235","DOI":"10.1371\/journal.pgen.1004235","article-title":"A central role for GRB10 in regulation of islet function in man","volume":"10","author":"Prokopenko","year":"2014","journal-title":"PLoS Genet"},{"key":"2022031223501123300_B25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ng.521","article-title":"Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge","volume":"42","author":"Saxena","year":"2010","journal-title":"Nat Genet"},{"key":"2022031223501123300_B26","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.2337\/db10-0502","article-title":"Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways [published correction appears in Diabetes 2011 60:1050\u20131051]","volume":"59","author":"Soranzo","year":"2010","journal-title":"Diabetes"},{"key":"2022031223501123300_B27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00592-009-0160-1","article-title":"Angiotensin-converting enzyme gene polymorphism is associated with proliferative diabetic retinopathy: a meta-analysis","volume":"47","author":"Zhou","year":"2010","journal-title":"Acta Diabetol"},{"key":"2022031223501123300_B28","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2337\/dc10-0349","article-title":"Interactions among related genes of renin-angiotensin system associated with type 2 diabetes","volume":"33","author":"Yang","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031223501123300_B29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/tpj.2009.70","article-title":"A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor","volume":"10","author":"Chung","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"2022031223501123300_B30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11033-009-9648-6","article-title":"Angiotensin-converting enzyme gene polymorphism is associated with type 2 diabetes: a meta-analysis","volume":"37","author":"Zhou","year":"2010","journal-title":"Mol Biol Rep"},{"key":"2022031223501123300_B31","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41588-018-0241-6","article-title":"Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps","volume":"50","author":"Mahajan","year":"2018","journal-title":"Nat Genet"},{"key":"2022031223501123300_B32","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/00004872-200410000-00021","article-title":"Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity","volume":"22","author":"Furuhashi","year":"2004","journal-title":"J Hypertens"},{"key":"2022031223501123300_B33","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2337\/diabetes.53.6.1418","article-title":"Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo","volume":"53","author":"Vincent","year":"2004","journal-title":"Diabetes"},{"key":"2022031223501123300_B34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1113\/jphysiol.2005.101352","article-title":"Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans","volume":"571","author":"Goossens","year":"2006","journal-title":"J Physiol"},{"key":"2022031223501123300_B35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.biocel.2005.08.007","article-title":"Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes","volume":"38","author":"Tikellis","year":"2006","journal-title":"Int J Biochem Cell Biol"},{"key":"2022031223501123300_B36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1159\/000342776","article-title":"The renin-angiotensin system in the pathophysiology of type 2 diabetes","volume":"5","author":"Goossens","year":"2012","journal-title":"Obes Facts"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc19-1973","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/4\/835\/533029\/dc191973.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/4\/835\/533029\/dc191973.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:45:26Z","timestamp":1647143126000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/43\/4\/835\/35782\/ACE-and-Type-2-Diabetes-Risk-A-Mendelian"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,2,4]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc19-1973","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"type":"print","value":"0149-5992"},{"type":"electronic","value":"1935-5548"}],"subject":[],"published":{"date-parts":[[2020,2,4]]}}}